Mammal Patents (Class 800/14)
-
Publication number: 20120233713Abstract: The present invention relates to methods and systems for inducible ablation of neural cells, in particular non-proliferating cells, such as oligodendrocytes and Schwann cells. The methods and systems include an animal model that can be specifically induced to display phenotypic traits or characteristics of a demyelination condition. The methods and systems disclosed herein are useful for drug screening, by identifying compounds or agents that promote remyelination or reversal of phenotypic traits or characteristics of demyelination conditions.Type: ApplicationFiled: September 2, 2010Publication date: September 13, 2012Inventors: Brian Popko, Maria Traka
-
Patent number: 8263822Abstract: Disclosed are a composition for inhibiting the expression of GA733-2 or for detecting GA733-2, which comprises TREM-2 gene or protein, a transgenic animal containing same, and a method using the same.Type: GrantFiled: February 18, 2009Date of Patent: September 11, 2012Assignee: GLO BiotechInventors: Hyung-Sik Kang, Eun-Mi Kim, Dong-Hern Kim, Ha-Rim Choi, Eun-Hee Lee, Il-Soo Kim, Chang-Eon Park
-
Patent number: 8263821Abstract: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a particular embodiment, said recombinant polypeptide comprises or consists of the Aequorin and GFP linked by a linker allowing chemiluminescence resonance energy transfer (CRET), and optionally comprises a peptidic fragment capable of targeting said recombinant polypeptide into a specific cellular domain or compartment. The present invention also concerns a transgenic non-human animal expressing said recombinant polypeptide sensitive to calcium concentration, in conditions enabling the in vivo monitoring of Ca2+ dynamics.Type: GrantFiled: January 11, 2005Date of Patent: September 11, 2012Assignee: Institut PasteurInventors: Philippe Brulet, Kelly Rogers, Sandrine Picaud
-
Publication number: 20120222143Abstract: Compositions and methods for use of TALENs to make genetically modified livestock are set forth. The methods may include reporters for selecting cells or embryos that have been modified by TALENs for use as progenitor cells to make founder animals.Type: ApplicationFiled: February 24, 2012Publication date: August 30, 2012Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
-
Patent number: 8247643Abstract: A genetically modified animal that includes an introduced DNA including a functionally linked aryl hydrocarbon receptor-binding enhancer located 5?-upstream of a tyrosine hydroxylase gene, promoter of any type, reporter gene, and poly(A) addition signal.Type: GrantFiled: September 14, 2009Date of Patent: August 21, 2012Assignee: Kabushiki Kaisha ToshibaInventors: Eiichi Akahoshi, Mitsuko Ishihara, Tomoyuki Shishido, Shigehisa Kawata
-
Publication number: 20120204281Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 9, 2012Inventors: Clifford J. WOOLF, Tarek A. Samad
-
Publication number: 20120204280Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 9, 2012Inventors: Clifford J. Woolf, Tarek A. Samad
-
Publication number: 20120198574Abstract: The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.Type: ApplicationFiled: December 21, 2011Publication date: August 2, 2012Applicant: Case Western Reserve UniversityInventors: Stephen M. Selkirk, Robert H. Miller
-
Patent number: 8232447Abstract: It is an object to provide a gene-modified non-human animal having inactivated MGAT2 gene and a gene-modified non-human animal cell, which are useful for the search of the function of MGAT2 in vivo. It is another object to provide a method for screening of a compound capable of inhibiting the activity of MGAT2 and a compound capable of inhibiting the activity of MGAT2. It is further another object to provide a method for detecting a disease induced by abnormal lipid metabolism based on the expression level or activity of MGAT2. A method for screening of a compound by using a gene-modified non-human mammal having the artificially inhibited expression of MGAT2 gene and a cell thereof enable to prevent or treat a disease induced by abnormal lipid metabolism. Also a screening of a compound capable of inhibiting or enhancing the function of MGAT2 enables to prevent or treat a disease induced by abnormal lipid metabolism.Type: GrantFiled: November 30, 2007Date of Patent: July 31, 2012Assignee: MSD K.K.Inventors: Katsumi Aragane, Katsuya Ohbuchi, Yoshitaka Tamai, Naomoto Harada, Naomi Murai, Yoshiki Ito, Jun Kusunoki, Yukina Tokushima, Takaharu Maruyama
-
Publication number: 20120192298Abstract: The present invention encompasses a method for creating an animal or cell with at least one chromosomal edit. In particular, the invention relates to the use of targeted zinc finger nucleases to edit chromosomal sequences. The invention further encompasses an animal or a cell created by a method of the invention.Type: ApplicationFiled: July 23, 2010Publication date: July 26, 2012Applicant: SIGMA ALDRICH CO. LLCInventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20120185954Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: November 4, 2011Publication date: July 19, 2012Applicant: INTREXON CorporationInventors: Subba Reddy PALLI, Mohan Basavaraju Kumar
-
Patent number: 8222478Abstract: Provided herein are novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods relating thereto. Such novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods provide conditional overexpression of genes, such as myostatin, and transgenic animals conditionally overexpression genes, such as myostatin.Type: GrantFiled: March 5, 2009Date of Patent: July 17, 2012Assignee: Charles Drew University of Medicine and ScienceInventor: Suzanne Porszasz-Reisz
-
Publication number: 20120180150Abstract: The instant invention provides an inositol 1,4,5-triphaosphate receptor (IP3R)-binding protein and its transgenic non-human mammalian animal. The inositol 1,4,5-triphaosphate receptor-binding protein comprises an inositol 1,4,5-triphaosphate receptor-binding protein with a protein including KRAP protein (SQ ID NOS. 1-4) bound to inositol 1,4,5-triphosphate (IP3R) protein (SQ ID NOS. 5-8). The IP3R activity inhibitor contains the IP3R-binding protein as a major ingredient. The transgenic non-human mammal of the instant invention carries the IP3R-binding protein. The site of binding of the KRAP protein to the IP3R protein is located in an amino acid region composed of 19 amino acids ranging from amino acid 200 to amino acid 218 of the mouse KRAP protein and an 19-amino acid region corresponding to that of the mouse KRAP protein for any animal species other than mouse.Type: ApplicationFiled: September 28, 2010Publication date: July 12, 2012Inventors: Takahiro Fujimoto, Senji Shirasawa
-
Publication number: 20120180151Abstract: The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain an exogenous gene encoding a recombinant fusion protein, wherein the presence, and expression, of said recombinant fusion protein renders said genetically-modified non-human animal sterile. Tools for generating such sterile genetically-modified non-human animal as well as methods of use thereof are also provided.Type: ApplicationFiled: August 26, 2010Publication date: July 12, 2012Inventors: Pawal Pelczar, Thorsten Buch, Antoine Peters
-
Publication number: 20120171114Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: November 29, 2011Publication date: July 5, 2012Inventor: Jean-François Haeuw
-
Publication number: 20120171222Abstract: The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Applicant: The Board of Regents of the University of Texas SystemInventors: Partha Sarkar, Tetsuo Ashizawa, Weidong Xu
-
Publication number: 20120167239Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: February 20, 2002Publication date: June 28, 2012Applicant: TUTOGEN MEDICAL GMBHInventors: Subba Reddy Palli, Marianna Z. Kapitskaya
-
Publication number: 20120167238Abstract: Compositions and methods that allow for the rapid detection and accurate quantification of any polypeptides of interest are provided. Compositions include isolated polypeptides comprising at least one universal peptide tag, as well as isolated polynucleotides encoding such polypeptides. The universal peptide tags can be quantified by methods including, but not limited to, mass spectrometry, and can act as surrogates for determining the concentration of the polypeptides comprising the universal peptide tags. Methods provide for the detection and/or quantification of any polypeptides of interest that comprise at least one universal peptide tag, including methods using mass spectroscopy techniques. Methods are also provided for producing hosts, or cells or parts thereof, that comprise polypeptides comprising at least one universal peptide tag. Hosts, or cells, or parts thereof, include mammalian, bacterial, insect, yeast, viral or plant.Type: ApplicationFiled: December 22, 2011Publication date: June 28, 2012Applicant: Pioneer Hi-Bred International, Inc.Inventors: Xuehua Hu, Michaela Owens, Clara Alarcon, Xiping Niu
-
Publication number: 20120159654Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences involved in ADME and toxicology. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence involved in ADME and toxicology and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences involved in ADME and toxicology.Type: ApplicationFiled: July 23, 2010Publication date: June 21, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20120159653Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with MD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study MD development and methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with MD.Type: ApplicationFiled: July 23, 2010Publication date: June 21, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20120159660Abstract: The amino acid and nucleic acid sequences of a ?5-desaturase enzyme and a ?8-desaturase enzyme are disclosed. The nucleic acid sequences can be used to design recombinant DNA constructs and vectors. These vectors can then be used to transform various organisms, including for example, plants and yeast. The transformed organisms will then produce polyunsaturated fatty acids. The amino acid sequences are useful for generating enzyme-specific antibodies that are useful for identifying the desaturases.Type: ApplicationFiled: February 27, 2012Publication date: June 21, 2012Inventors: John A. Browse, James G. Wallis, Jennifer L. Watts
-
Publication number: 20120151609Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allo dynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use.Type: ApplicationFiled: August 20, 2010Publication date: June 14, 2012Inventors: Eric M. Ostertag, John Stuart Crawford, Karin Westlund High
-
Publication number: 20120151613Abstract: The invention provides functional mutants of activation-induced cytidine deaminase (AID) protein that have increased activity as compared to a wild-type AID protein. The invention also provides nucleic acids encoding the functional AID mutants, and vectors and cells comprising the nucleic acids. The invention further provides methods of using the functional mutant AID proteins.Type: ApplicationFiled: April 5, 2010Publication date: June 14, 2012Applicant: Medical Research CouncilInventors: Meng Wang, Zizhen Yang, Cristina Rada, Michael Neuberger
-
Patent number: 8187572Abstract: The present invention provides a method of producing diabetic rats, and a method for identifying compounds that reverse diabetes in said rats.Type: GrantFiled: July 5, 2006Date of Patent: May 29, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Agnes Benardeau, Emmanuelle Hainaut, Philippe Verry
-
Publication number: 20120128682Abstract: An isolated human Apolipoprotein L-I corresponding to a wild type human Apolipoprotein sequence is modified by a deletion at its C-terminal end.Type: ApplicationFiled: August 18, 2010Publication date: May 24, 2012Applicant: Universite Libre de BruxellesInventors: Etienne Pays, Laurence Lecordier, Benolt Vanhollebeke
-
Publication number: 20120124685Abstract: The present invention provides compositions, methods, and kits for generating and isolating tagged nuclei of specific cell types with a high yield and purity. The compositions, methods, and kits provided herein comprise expressing in a cell a nuclear envelope tagging fusion polypeptide comprising a nuclear envelope targeting domain and an affinity reagent binding region. In some embodiments, expression of the fusion polypeptide is under the control of a cell type-specific promoter. Some embodiments also comprise expressing in a cell a biotin ligase, wherein the affinity reagent binding region comprises a biotin ligase accepting site, and wherein at least one of the nuclear envelope tagging fusion polypeptide and the biotin ligase is expressed under the control of a cell type-specific promoter.Type: ApplicationFiled: September 15, 2011Publication date: May 17, 2012Inventors: Steven Henikoff, Roger B. Deal, Gilbert Lee Henry
-
Publication number: 20120117674Abstract: Sequences are provided that are capable of directing circular adeno-associated virus replication, useful in vectors for providing therapeutic agents to a subject in need thereof. The vectors of the invention are particularly useful in the treatment of acute medical conditions requiring rapid gene expression. Further provided are methods for producing packaged defective viral vectors.Type: ApplicationFiled: November 22, 2011Publication date: May 10, 2012Inventors: Michael G. Kaplitt, Sergei Moussatov
-
Patent number: 8173859Abstract: An epilepsy model animal (CHRNA4:S284L) developing spontaneous epileptic seizure during sleep, which is a nonhuman animal established by ontogenesis of a totipotent cell into which a polynucleotide encoding nonhuman mutant CHRNA4 is introduced and having said polynucleotide in its somatic chromosome, or a progeny of the nonhuman animal, wherein said nonhuman mutant CHRNA4 has the corresponding mutation of human mutant CHRNA4 in which the 284th Ser of SEQ ID NO: 1 is substituted by Leu. The epilepsy model animal has gene abnormality homologous to human chromosomal dominant nocturnal frontal lobe epilepsy and a symptom (epileptic seizure during sleep) the same as that of human autosomal dominant nocturnal frontal lobe epilepsy.Type: GrantFiled: February 23, 2005Date of Patent: May 8, 2012Assignee: Japan Science and Technology AgencyInventors: Shinichi Hirose, Sunao Kaneko, Motohiro Okada, Ryo Saito
-
Patent number: 8173860Abstract: The invention provides, in part, methods for the production of proteins in a transgenic non-human mammal, wherein the proteins are transported from the blood to the mammary gland for secretion in milk. The transport of the protein to the mammary gland and/or milk is facilitated by binding to a transport receptor in the mammary gland.Type: GrantFiled: April 20, 2007Date of Patent: May 8, 2012Assignee: GTC Biotherapeutics, Inc.Inventors: Harry M. Meade, Daniel Pollock
-
Publication number: 20120110686Abstract: The present invention relates to systems and methods for modulating gene expression and applications thereof. Provided is a novel expression system to generate RNaseZ and RNA polymerase III dependent RNAs to regulate genes and control the timing and the location of the regulation by supplying synthetic or expressed oligonucleotide antisense to a small RNA.Type: ApplicationFiled: April 19, 2010Publication date: May 3, 2012Inventors: Mark A. Kay, Dirk Haussecker
-
Publication number: 20120090043Abstract: The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins.Type: ApplicationFiled: June 30, 2010Publication date: April 12, 2012Applicant: UNIVERSITE DE LIEGEInventors: Jean-Claude Twizere, Nicolas Simonis
-
Publication number: 20120084871Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.Type: ApplicationFiled: February 14, 2011Publication date: April 5, 2012Applicant: Schering CorporationInventors: Scott Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
-
Publication number: 20120084872Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.Type: ApplicationFiled: June 7, 2011Publication date: April 5, 2012Applicant: Cold Spring Harbor LaboratoryInventors: Ross Dickins, Gregory J. Hannon, Scott W. Lowe
-
Publication number: 20120079614Abstract: The invention concerns compounds, compositions and methods for the treatment of skin cells. Described herein are CD109 polypeptides and uses thereof for the in vivo treatment of various skin disorders, including skin fibrosis, skin scarring, wound healing and psoriasis.Type: ApplicationFiled: February 19, 2010Publication date: March 29, 2012Applicant: The Royal Institution for the Advancement of Learning/McGill UniversityInventors: Anie Philip, Joshua Vorstenbosch, Carter Li, Kenneth Finnson, Hahn Soe-Lin, Xiao-Yong Man, Albane Bizet, Hasan Al-Ajmi
-
Publication number: 20120073003Abstract: The present invention relates to methods and compositions for preventing the occurance or progression of a cancer or pre-cancerous condition associated with expression, or over-expression of human cytidine deaminases of the APOBEC3 family. The invention also relates to drug screening assays designed to identify compounds that regulate the activity, or level of expression, of hA3A, hA3C and hA3H. The invention further relates to transgenic mice, as well as cells derived from said mice, that have been genetically engineered to express, or over-express hA3A, hA3C and/or hA3H. Such mice may be utilized to screen for, or identify, compounds that modulate the activity, or expression, of the human cytidine deaminases. The present invention also provides topical compositions such as cosmetic lotion, crème, or sunscreen for use on the skin, which comprise one or more inhibitors of human cytidine deaminase activity.Type: ApplicationFiled: May 9, 2011Publication date: March 22, 2012Applicant: INSTITUT PASTEURInventors: Simon Wain-Hobson, Jean-Pierre Vartanian
-
Publication number: 20120066782Abstract: The present invention relates to a kit for detection of association of a peripheral cellular membrane binding protein with cellular membranes in living cells and methods thereof. The kit includes a first nucleic acid construct comprising a first nucleic acid molecule encoding a first fusion protein comprising a peripheral cellular membrane binding protein or membrane binding domain thereof operatively coupled to DNA binding and transactivation domains of a naturally occurring or chimeric transcription factor and a first promoter operatively associated with the first nucleic acid molecule. A second nucleic acid construct comprises a second nucleic acid molecule encoding a reporter protein and a second promoter responsive to the DNA binding and transactivation domains of the first fusion protein. The second promoter is operatively associated with the second nucleic acid molecule. Activation of the second promoter results in expression of the reporter protein. Also disclosed is a transgenic non-human animal.Type: ApplicationFiled: August 31, 2011Publication date: March 15, 2012Applicant: NEW YORK UNIVERSITYInventors: Mark R. PHILIPS, Nicole FEHRENBACHER, Joseph WYNNE
-
Publication number: 20120066781Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate.Type: ApplicationFiled: May 20, 2010Publication date: March 15, 2012Inventors: David P. Weiner, Arne I. Solbak, JR., Ryan McCann
-
Publication number: 20120066776Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: August 19, 2011Publication date: March 15, 2012Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Patent number: 8124832Abstract: Provided is a method for producing a cloned dog by enucleating an oocyte of a dog to produce an enucleated oocyte, transferring a somatic cell of the dog into the enucleated oocyte, carrying out electrofusion under optimized conditions to produce a nuclear transfer embryo, and transferring the nuclear transfer embryo into its surrogate mother.Type: GrantFiled: June 13, 2007Date of Patent: February 28, 2012Assignee: Seoul National University Industry FoundationInventors: Byeong Chun Lee, Sung Keun Kang, Dae Yong Kim, Min Kyu Kim, Goo Jang, Hyun Ju Oh, M. Shamim Hossein, Fibrianto Yuda, Hye Jin Kim, So Gun Hong, Jung Eun Park, Joung Joo Kim
-
Patent number: 8124829Abstract: The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.Type: GrantFiled: October 20, 2010Date of Patent: February 28, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan
-
Publication number: 20120047585Abstract: The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.Type: ApplicationFiled: August 8, 2008Publication date: February 23, 2012Applicant: Medarex, Inc.Inventors: Daniel K. Rohrer, Nancy Amelia Black, Nils Lonberg
-
Publication number: 20120042400Abstract: Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided.Type: ApplicationFiled: November 29, 2010Publication date: February 16, 2012Applicant: GENENTECH, INC.Inventors: Avi J. Ashkenazi, Austin Gurney
-
Publication number: 20120030782Abstract: The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germline transgenic animals by direct injection of nucleic acid molecules into animals.Type: ApplicationFiled: October 4, 2011Publication date: February 2, 2012Applicant: The Regents of The University of MichiganInventors: Lisa S. D. Emmett, Theresa Gratsch, K. Sue O'Shea, J. Matthew Velkey, Michael J. Welsh, William Wu
-
Publication number: 20120023599Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding cytochrome P450 (CYP) proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence encoding CYP proteins, as well as methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 26, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Victoria Brown-Kennerly
-
Patent number: 8088968Abstract: The invention relates to the generation of non-human transgenic animals comprising a reporter construct for producing a detectable amount of a reporter molecule operably linked to a transcriptional regulatory nucleic acid molecule from the human CYP3A4 gene located between the initiation of transcription site of the gene and a position located 13,000 nucleotides upstream from the site. The invention also relates to the use of these animals for determining the effect of a compound, particularly, but not exclusively, a xenobiotic or steroid, on the regulation of expression of the CYP3A4 gene in a human.Type: GrantFiled: May 8, 2009Date of Patent: January 3, 2012Assignee: The University of SydneyInventors: Christopher Liddle, Bryan James Goodwin, Graham Robertson
-
Publication number: 20110318367Abstract: In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided.Type: ApplicationFiled: December 11, 2009Publication date: December 29, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Peter J. Tontonoz, Noam Zelcer
-
Publication number: 20110314563Abstract: A non-human mammal containing an endogenous lambda light chain gene locus, an endogenous kappa light chain gene locus and an endogenous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge but said loci have been mutated so that the ability to form functional immunoglobulin tetramers comprising re-arranged heavy and light chains produced from said mutated loci has been substantially reduced or eliminated.Type: ApplicationFiled: November 30, 2009Publication date: December 22, 2011Inventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Mariuns Johannes Van Haperen
-
Publication number: 20110302666Abstract: A spermatogonial stem cell line that is derived from testes rats characterized by a desirable genetic background can serve as a source for cells to transplant into male-sterile recipient animals that are immuno-compatible with the spermatogonial line. Rat cells thus transplanted readily develop into fertilization-competent, haploid male gametes, with little or no endogenous sperm competition generated by the testes of the male-sterile recipient. This approach, constituting the first vector system for the use of rat spermatogonial lines from in vitro culture in generating mutant rats on a desired genetic background, effects maximal germline transmission of donor haplotypes from the transplanted spermatogonial cells.Type: ApplicationFiled: December 1, 2009Publication date: December 8, 2011Inventor: Franklin Kent Hamra
-
Publication number: 20110296544Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: May 16, 2011Publication date: December 1, 2011Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Alqun Li, Tao He, Ian McCaffery
-
Publication number: 20110296545Abstract: Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain ‘cleavage-inhibiting’ glutamine (Q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position ?5 relative to the cleavage site. Mutagenesis of Q at position ?5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(?5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods for treating conditions and/or diseases associated with M. haemolytica (e.g.Type: ApplicationFiled: February 2, 2010Publication date: December 1, 2011Applicant: Washington State UniversityInventors: Subramaniam Srikumaran, Sudarvili Shanthalingam